Imre forced to re-negotiate Baxter Healthcare deal:

Imre has begun re-negotiation of its Prosorba column distribution deal with Baxter Healthcare, following the US FDA's decision in January to block the proposed relabelling of Imre's Prosorba columns (see Clinica No 638, p 19). The FDA ruled that the approved indication for the Prosorba column will remain idiopathic thrombocytopenic purpura rather than be changed to immune thrombocytopenic purpura as requested by Imre in March 1993. In April 1994, Imre entered a ten-year exclusive distribution agreement with Baxter (see Clinica No 609, p 11). The start of the discussions with Baxter has forced Imre to postpone the second round of its previously announced private placement.